Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) will host a virtual investor event on September 17, 2021, from 10:00 AM to 12:30 PM ET, to discuss clinical data for rebastinib and vimseltinib ahead of the ESMO Congress 2021. Key speakers include Dr. Robert L. Coleman and Dr. William D. Tap. The event will be webcast live and available for replay on Deciphera's website. Deciphera is committed to developing innovative cancer treatments, highlighted by its FDA-approved drug QINLOCK, used for fourth-line gastrointestinal stromal tumors.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET.

Deciphera’s senior executive team will be joined by the following key opinion leaders at the event:

• Dr. Robert L. Coleman, M.D., FACOG, FACS, Gynecologic Oncologist and Chief Scientific Officer at US Oncology Research
• William D. Tap, M.D., Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center

A live webcast of the event may be accessed through the “Investors” section of Deciphera’s website at www.deciphera.com. A replay of the webcast will be available following the event.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, China, Hong Kong, and Taiwan. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005108/en/

Investor Relations:

Jen Robinson

Deciphera Pharmaceuticals, Inc.

jrobinson@deciphera.com

781-906-1112

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

What is the date and time of Deciphera Pharmaceuticals' upcoming investor event?

The investor event will take place on September 17, 2021, from 10:00 AM to 12:30 PM ET.

Who are the key opinion leaders participating in Deciphera's investor event?

Dr. Robert L. Coleman and Dr. William D. Tap will participate in the event.

Where can I watch the Deciphera Pharmaceuticals investor event?

The event can be accessed via a live webcast on Deciphera's website.

What drugs will be discussed during the Deciphera investor event?

The event will review clinical data for the drugs rebastinib and vimseltinib.

What is QINLOCK and its approval status?

QINLOCK is Deciphera's FDA-approved drug for treating fourth-line gastrointestinal stromal tumors (GIST).